Keros Therapeutics (NASDAQ:KROS) Given New $23.00 Price Target at Oppenheimer

Keros Therapeutics (NASDAQ:KROS) had its price target lowered by Oppenheimer from $63.00 to $23.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

KROS has been the subject of a number of other reports. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Scotiabank dropped their price target on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday, December 13th. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Finally, Wells Fargo & Company boosted their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $70.22.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $10.52 on Thursday. The stock has a market capitalization of $426.17 million, a PE ratio of -2.02 and a beta of 1.43. The business’s 50 day simple moving average is $38.65 and its 200 day simple moving average is $47.61. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the company posted ($1.33) earnings per share. The business’s revenue was up 4750.0% on a year-over-year basis. As a group, research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. raised its holdings in shares of Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Alkeon Capital Management LLC raised its stake in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock valued at $24,493,000 after buying an additional 223,155 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Keros Therapeutics by 814.6% during the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares in the last quarter. Finally, FMR LLC raised its position in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.